

Literatur

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. *JAMA* 2002; 287: 2570–2581.
2. The IDF consensus worldwide definition of the Metabolic Syndrome. International Diabetes Federation 2006.
3. Rydén L et al. The management of the type 2 diabetic patient with hypertension – too late and too little: suggested improvements. *Blood Press* 2008; 17: 250–259.
4. Poirier P et al. American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. *Circulation* 2006; 113: 898–918.
5. Zipes DP et al. Heart Disease; a textbook of cardiovascular medicine. Elsevier Saunders 2005(7th Ed.): 959–987.
6. Sharma ES, Engeli S. The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. *J Cardiometab Syndr* 2006; 1: 29–35.
7. Vogt B, Bochud M, Burnier M. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. *Semin Nephrol* 2007; 27: 529–537.
8. Sarzani R et al. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. *J Hypertens* 2008; 26: 831–843.
9. Matayoshi T et al. Relationship between insulin resistance and the renin-angiotensin system: analysis for patients with essential and renovascular hypertension. *Clin Exp Hypertens* 2007; 29: 479–487.
10. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. *Nat Clin Pract Endocrinol Metab* 2008; 4: 444–452.
11. Aso Y. Cardiovascular disease in patients with diabetic nephropathy. *Curr Mol Med* 2008; 8: 533–543.
12. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ* 1998; 317: 703–713.
13. Klein R et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? *Arch Intern Med* 1989; 149: 2427–2432.
14. Pyörälä M et al. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. *Arterioscler Thromb Vasc Biol* 2000; 20: 538–544.
15. Isomaa B et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001; 24: 683–689.
16. Smiley T, Oh P, Shane LG. The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes – a systematic review. *Can J Cardiol* 2001; 17: 797–805.
17. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet* 1998; 351: 1755–1762.
18. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. *J Hypertens* 1993; 11: 319–325.
19. Schrier RW et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. *Kidney Int* 2002; 61: 1086–1097.
20. Brown MJ et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). *Lancet* 2000 356: 366–372.
21. Hansson L et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet* 2000; 356: 359–365.
22. Lindholm LH et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. *J Hypertens* 2000; 18: 1671–1675.
23. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002; 288: 2981–2997.
24. Niskanen L et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. *Diabetes Care* 2001; 24: 2091–2096.
25. Tatti P et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. *Diabetes Care* 1998; 21: 597–603.
26. Estacio RO et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *N Engl J Med* 1998; 338: 645–652.
27. Lindholm LH et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; 359: 1004–1010.
28. Zanchetti A et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. *J Hypertens* 2006; 24: 2163–2168.
29. Stojiljkovic L, Behnia R. Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials. *Curr Pharm Des* 2007; 13: 1335–1345.
30. Parving HH et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. *N Engl J Med* 2008; 358: 2433–2446.
31. Parving HH et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. *Nephrol Dial Transplant* 2009; 24: 1663–1671.
32. Nilsson PM et al. European Society of Hypertension Scientific Newsletter: update on hypertension management: prevention of type 2 diabetes mellitus with antihypertensive drugs. *J Hypertens* 2006; 24: 2478–2482.
33. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *Lancet* 2007; 369: 201–207.
34. REAM (Diabetes REDuction Assessment with ramipril and rosiglitazone Medication) Trial Investigators et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. *Lancet* 2006; 368: 1096–1105.